Hepatitis C prevalence in children with perinatal human immunodeficiency virus infection enrolled in a long-term follow-up protocol.
نویسندگان
چکیده
OBJECTIVE To evaluate the prevalence of hepatitis C virus (HCV) infection in children with perinatal human immunodeficiency virus (HIV) infection. DESIGN Cross-sectional substudy. SETTING Multicenter study from 41 sites in the United States. PATIENTS Children with perinatal HIV infection were randomly selected from a large, long-term, follow-up protocol. MAIN OUTCOME MEASURE Hepatitis C infection was defined as having positive test results on both HCV antibody and HCV RNA assays. RESULTS Five hundred thirty children enrolled in the substudy; definitive HCV test results were available for 525 children. Eighty-three percent were of a minority race or ethnicity. They were equally distributed by sex, had a median age of 10.7 years, and were relatively healthy, with 75% having CD4+ lymphocyte counts greater than 500 cells/mm3. Eight of 525 children (1.5%; 95% confidence interval [CI], 0.7%-3.0%) infected with HIV were coinfected with HCV. In contrast, the rate of HCV infection in a serosurvey of more than 2700 children aged 6 to 11 years from the National Health and Nutrition Examination Survey was 0.2% (95% CI, 0.04%-0.6%). In our study, there were no differences between children coinfected with HIV and HCV and those without HCV infection in terms of demographic characteristics, CD4+ or CD8+ T-lymphocyte counts, HIV 1 RNA levels, preterm or mode of delivery, or liver disease; however, the number of children coinfected with HIV and HCV was small. CONCLUSION While HCV prevalence infection rates are low in children with perinatal HIV infection, they are 8 to 10 times higher than reported in HCV serosurveys of children in the United States.
منابع مشابه
The Prevalence of Hepatitis B, Hepatitis C, and Human Immunodeficiency Virus Infections among β-thalassemia Major: A Multicenter Survey in Lorestan, West of Iran
Background: Although regular frequent blood transfusion improves overall survival of multi-transfused patients like β-thalassemic ones, it carries a definite risk of infection with blood-borne viruses such as viral hepatitis. This study was done to determine seropositivity of hepatitis B virus (HBV), hepatitis C virus (HCV), and Human Immunedeficiency Virus (HIV) infections among β-th...
متن کاملThe Prevalence of Blood-Borne Viral Infection (HBV, HCV, HIV) among Hemophilia Patients in Hamedan Province of Iran
Background: Hemophilia A and B are the most frequent congenital coagulation disorders. This study was conducted to determine the prevalence of hepatitis B, C and human immunodeficiency viruses among hemophilic patients in Hamadan, Iran. Patients and Methods: In this study, patients with hemophilia A and B treated in Hamedan Hemophilia Center, Hamedan, Iran, were screened for hepatitis B, C and...
متن کاملLong Term Follow up Study on a Large Group of Patients with Congenital Factor XIII Deficiency Treated Prophylactically with Fibrogammin P®
Factor XIII deficiency (FXIIID) is an extremely rare hemorrhagic disorder with a prevalence of 1/3-5 million. Management of disease is performed by fresh frozen plasma (FFP), Cryoprecipitate (CP) or FXIII concentrate (Fibrogammin P®). Our objective was to assess safety and effectiveness of Fibrogammin P® in patients with FXIIID. For this purpose we designed this long-term follow up study on a l...
متن کاملSeroprevalence of Human Immunodificiency Virus (HIV) and Hepatitis C Infection In Hemophilic Patients In Iran
Background and Objective: Although transfusion therapy has lead to great improvement in longevity for hemophiliacs, but there have been tragic setbacks especially from transmission of human immunodeficiency virus (HIV) and hepatitis C virus (HCV) .HIV was reported to increase the rate of HCV-related liver failure by 4.2 times. In this study, we aimed to determine the seroprevalence of HIV an...
متن کاملLong Term Follow up Study on a Large Group of Patients with Congenital Factor XIII Deficiency Treated Prophylactically with Fibrogammin P®
Factor XIII deficiency (FXIIID) is an extremely rare hemorrhagic disorder with a prevalence of 1/3-5 million. Management of disease is performed by fresh frozen plasma (FFP), Cryoprecipitate (CP) or FXIII concentrate (Fibrogammin P®). Our objective was to assess safety and effectiveness of Fibrogammin P® in patients with FXIIID. For this purpose we designed this long-term follow up study on a l...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Archives of pediatrics & adolescent medicine
دوره 158 10 شماره
صفحات -
تاریخ انتشار 2004